Bulimia Nervosa
📧 Sign up to get email alerts when something new happens for Bulimia Nervosa.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2016-12-27FDA Approved: FLUOXETINE — Supplemental Application (Saptalis Pharmaceuticals, LLC.)
The FDA approved a supplemental application for fluoxetine (generic) from Saptalis Pharmaceuticals, LLC, for continued marketing under the a…
-
CLINICAL_TRIALS trial_result · 2016-11-18Clinical Trial Update: Improving Treatment Engagement for Adolescents With Bulimia Nervosa [NA]
This clinical trial update reports on a completed study aimed at improving treatment engagement among adolescents with bulimia nervosa. No d…
-
FDA approval · 2016-10-21FDA Approved: FLUOXETINE — Original Application (Torrent Pharmaceuticals Limited)
The FDA approved Torrent Pharmaceuticals Limited's original application for fluoxetine, authorizing the marketing of a generic fluoxetine pr…
-
FDA approval · 2016-08-19FDA Approved: FLUOXETINE HYDROCHLORIDE — Original Application (Endo USA, Inc.)
FDA approves Endo USA, Inc.'s fluoxetine hydrochloride as an Original Application, providing a generic version of fluoxetine hydrochloride.
-
CLINICAL_TRIALS trial_result · 2016-08-08Clinical Trial Update: Description and Evaluation of Eating Disorders in Elite Athletes (TCA SHN)
A clinical trial update notes that the study on describing and evaluating eating disorders in elite athletes (TCA SHN) has been terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2016-08-01FDA Approved: PROZAC — Supplemental Application (Dista Products Company)
FDA approves a supplemental application for PROZAC (fluoxetine hydrochloride) submitted by Dista Products Company.
-
CLINICAL_TRIALS trial_result · 2016-07-25Clinical Trial Update: Transcranial Treatments in Eating Disorders [NA]
A clinical trial evaluating transcranial treatments for eating disorders was terminated.
-
CLINICAL_TRIALS trial_result · 2016-07-20Clinical Trial Update: Focused Versus Enhanced Cognitive Behavioral Therapy for Treating Women With Bulimia Nervosa [Phase 2]
A Phase 2 trial comparing focused cognitive-behavioral therapy to enhanced cognitive-behavioral therapy for bulimia nervosa in women has com…
-
CLINICAL_TRIALS trial_result · 2016-05-24Clinical Trial Update: Motivating Factors That Play a Role in Bulimia Nervosa
A clinical trial investigated motivational factors that influence bulimia nervosa, and the study has completed.
-
CLINICAL_TRIALS trial_result · 2016-05-18Clinical Trial Update: Engaging Latino Families in Eating Disorders Treatment [NA]
A clinical trial update indicates the study on engaging Latino families in eating disorders treatment has completed.
-
CLINICAL_TRIALS trial_result · 2016-05-16Clinical Trial Update: Rapid Response to Day Hospital Treatment in Bulimia Nervosa and Purging Disorder [NA]
A University Health Network clinical trial examined rapid response to day-hospital treatment for bulimia nervosa and purging disorder. The s…
-
CLINICAL_TRIALS trial_result · 2016-05-03Clinical Trial Update: Smartphone Technology and CBT-GSH in Binge Eaters [Phase 1]
Phase 1 trial evaluating smartphone-based CBT-GSH for binge eating disorders has completed; no efficacy results are provided in the summary.
-
CLINICAL_TRIALS trial_result · 2016-03-23Clinical Trial Update: Transcranial Magnetic Stimulation and Bulimic Craving [NA]
A completed clinical trial evaluated transcranial magnetic stimulation for bulimic cravings in bulimia nervosa.
-
FDA approval · 2016-03-14FDA Approved: FLUOXETINE — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
The FDA approved a supplemental application from Quallent Pharmaceuticals Health LLC to market fluoxetine hydrochloride as a generic product…
-
FDA approval · 2016-01-12FDA Approved: FLUOXETINE — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved a supplemental application for fluoxetine from Alembic Pharmaceuticals Limited.
-
FDA label_change · 2016-01-10FDA Approved: FLUOXETINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for fluoxetine from Teva Pharmaceuticals USA, Inc. to update the product labeling.
-
FDA approval · 2015-11-24FDA Approved: PROZAC — Supplemental Application (Dista Products Company)
FDA approved a supplemental application for Prozac (fluoxetine hydrochloride) submitted by Dista Products Company.
-
CLINICAL_TRIALS research · 2015-11-03Clinical Trial Update: Common Decision Making Deficits in Suicidal Behaviors and Eating Disorders
Clinical trial update from Sheba Medical Center examining common decision-making deficits in individuals with anorexia nervosa and bulimia n…
-
CLINICAL_TRIALS withdrawal · 2015-07-15Clinical Trial Update: Topiramate Augmentation in Bulimia Nervosa Partial Responders [Phase 4]
A Phase 4 clinical trial evaluating topiramate augmentation in partial responders with bulimia nervosa has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2015-05-25Clinical Trial Update: Study of Treatment for Adolescents With Bulimia Nervosa [NA]
A completed clinical trial evaluating a treatment for adolescents with bulimia nervosa. The study status indicates the trial has finished.
-
FDA approval · 2015-03-16FDA Approved: FLUOXETINE — Original Application (Vensun Pharmaceuticals, Inc.)
The FDA approved Vensun Pharmaceuticals' original (ANDA) application for fluoxetine hydrochloride, establishing a generic fluoxetine product…
-
FDA approval · 2015-01-12FDA Approved: FLUOXETINE — Supplemental Application (Chartwell Governmental & Specialty RX, LLC)
FDA approved a supplemental application for a generic fluoxetine product (ANDA 076458) from Chartwell Governmental & Specialty RX, LLC. This…
-
CLINICAL_TRIALS research · 2014-12-03Clinical Trial Update: Efficiency of Repetitive Transcranial Magnetic Stimulation (rTMS) in Bulimia [NA]
A clinical trial evaluating the efficiency of repetitive transcranial magnetic stimulation (rTMS) in bulimia nervosa. The current study stat…
-
FDA approval · 2014-10-17FDA Approved: FLUOXETINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved Teva Pharmaceuticals USA, Inc.'s supplemental application for fluoxetine.
-
FDA approval · 2014-10-10FDA Approved: PROZAC — Supplemental Application (Dista Products Company)
FDA approved a supplemental application for Prozac (fluoxetine hydrochloride) submitted by Dista Products Company.